
Mr Raphael Ho
Chief Executive Officer
EverArc Pharmaceuticals
C30
Mr Raphael Ho is Chief Executive Officer of EverArc Pharmaceuticals, part of Everest Medicines. He has extensive commercial experience building, leading teams and commercialising assets across emerging markets and the Asia Pacific region.
Mr Ho joined Everest from Convatec where he was the Strategic Initiatives Lead for Emerging Markets driving the transformation of the China and Japan business and expansion into emerging markets. Prior to Convatec, he served as the Asia Pacific General Manager at LianBio, a NASDAQ-listed American biotechnology start-up bringing transformative medicines to patients in China and Asia, as well as the founding General Manager for a Southeast Asia cluster at Amgen.
Prior to Amgen, Mr Ho held various commercial and leadership positions with GlaxoSmithKline (GSK). In his penultimate role based out of GSK’s London headquarters as Global Commercial Director for the Bone / Oncology Business, he oversaw launches in 45 markets across Asia, Middle East and Latin America.
Mr Ho holds Double Masters from Waseda University, Tokyo (Management) and NTU and a B.Appl.Sc. (Hons) in Chemistry, NUS. He has consulted for organisations such as Globant, Nanyang Business School (Healthcare Advisory Board) and BioMedica Gmbh.




